If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
101
results.
Updated on
20/08/2026 [07:51:00]
Results 75 to 100 of 101
Absstract of: CN121992094A
The invention relates to a molecular marker for diagnosis, prognosis evaluation and treatment of cardiac fibrosis, and belongs to the technical field of biological medicines. The invention provides a molecular marker capable of diagnosing cardiac fibrosis, evaluating the severity of cardiac fibrosis, evaluating the prognosis of cardiovascular diseases accompanied with cardiac fibrosis or evaluating the prognosis of acute myocardial infarction. The molecular marker comprises a hepatocyte growth factor. Research finds that the HGF is remarkably increased in plasma of a patient with cardiac fibrosis, and the plasma HGF level of a patient with aortic valve stenosis is also remarkably increased before an operation, so that the HGF can be used for diagnosing cardiac fibrosis and evaluating the severity of cardiac fibrosis. Researches find that timely transient increase of the HGF in plasma of a patient with acute myocardial infarction is significantly related to good prognosis, and continuous low-level increase, continuous high-level increase, recurrence and delayed increase of the HGF are significantly related to poor prognosis, so that the HGF can be used for evaluating prognosis of acute myocardial infarction.
Absstract of: US20260128175A1
The present disclosure provides systems and methods for machine learning classification and assessment of disease based on gene expression data. In an aspect, a method for determining a disease state of a subject may comprise: (a) assaying a biological sample obtained or derived from the subject to produce a data set comprising gene expression measurements of the biological sample at each of a plurality of disease-associated genomic loci; (b) computer processing the data set to determine the disease state of the subject; and (c) electronically outputting a report indicative of the disease state of the subject. In some embodiments, the plurality of disease-associated genomic loci comprises single nucleotide polymorphisms (SNPs). In some embodiments, the disease comprises a lupus condition. In some embodiments, the disease comprises cardiovascular disease (CVD).
Absstract of: CN121975726A
The invention relates to a method for separating myocardial cell-derived small extracellular vesicles from in-vitro plasma in vitro and application of the myocardial cell-derived small extracellular vesicles. The method comprises the following steps: (1) providing a ligand capable of being specifically combined with a raney base receptor 2 protein RYR2; (2) separating total small cell extracellular vesicles from the in-vitro plasma sample; (3) co-incubating the ligand and total small extracellular vesicles, so that the ligand is specifically combined with the small extracellular vesicles which are derived from myocardial cells and express RYR2 on the surface, and a ligand-vesicle compound is formed; (4) combining the ligand-vesicle compound with a solid-phase carrier so as to separate the myocardial cell-derived extracellular vesicles of which the surfaces express RYR2 from the mixture; and (5) washing and/or eluting the ligand-vesicle compound combined on the solid-phase carrier to obtain enriched small extracellular vesicles derived from myocardial cells.
Absstract of: CN121975932A
The invention relates to a system and a method for ultrasensitive detection of microRNAs related to acute myocardial infarction. According to the method, the trans-cleavage activity of a designed circular RNA activator (CA-RNA) and Cas13a protein is utilized, Cas13a is activated through a target microRNA to cut a continuous uracil (U) structure in the CA-RNA, the circular conformation of the Cas13a is destroyed, a linear activator is released, and then multi-round cascade signal amplification is triggered. A centrifugal digital micro-fluidic chip is combined, a reaction system is divided into a large number of independent micro-chambers, positive micro-chambers are counted according to Poisson distribution, and accurate quantification of target microRNA is achieved. The system does not need reverse transcription and complex instruments, can complete detection within 15 minutes at 37 DEG C, has the detection limit reaching the almole level, has the advantages of simplicity and convenience in operation, high sensitivity, strong specificity, good universality and the like, and is suitable for early clinical diagnosis of acute myocardial infarction.
Absstract of: CN121971424A
The invention discloses a method for regulating and controlling pathological heart remodeling of an AAC model mouse by succinic acid, and belongs to the field of heart disease treatment. The method comprises the following steps: selecting 8-week-old male C57BL/6J mice, dividing the mice into a normal temperature group and a slight cold exposure group, and carrying out adaptive feeding; establishing a heart remodeling model through an AAC operation; performing 1.5% succinic acid aqueous solution and/or 1mg/mL broad-spectrum antibiotic intervention on the mouse for 4 weeks; the method comprises the following steps: collecting heart tissues, detecting heart remodeling related indexes through Masson staining, WGA staining, qPCR, Western blot and other methods, and evaluating an intervention effect. According to the invention, succinic acid is used for intervention in a slightly cold exposure environment, so that AAC model mouse pathological heart remodeling is effectively regulated and controlled, and a new method and thought are provided for research and treatment of heart remodeling diseases.
Absstract of: CN121971589A
The invention relates to the field of molecular biology and biological medicine, and particularly discloses an antithrombotic effect of Meteorin protein or gene. Experiments prove that after Meteorin protein is incubated, the platelet aggregation reaction can be remarkably inhibited, the platelet spreading area can be reduced, blood clot contraction can be delayed, and meanwhile ATP release and alpha particle release of platelets and activation of surface integrin alpha IIb beta 3 can be inhibited. In a whole thrombus experiment, the Meteorin protein can effectively inhibit the formation of arterial thrombosis. The Meteorin protein is a human endogenous protein, so that the Meteorin protein has relatively small side effects, has relatively high safety as a potential drug, and has a good industrialization prospect.
Absstract of: CN121978331A
The invention belongs to the technical field of ischemic stroke treatment, and discloses application of ULK1 possibly serving as a target spot for treating ischemic stroke. According to the invention, a photothrombotic stroke model is established, a ULK1 inhibitor SBI-0206965 (SBI), LYN1604 hydrochloride (LYN) and a ULK1 agonist are administered, and the ULK1 agonist is used for regulating the activity of ULK1 in vivo. Examples assess the outcome of sensory motor deficits, neuronal apoptosis, and microglia/macrophage activated neurological function. Immunofluorescence detection results show that ULK1 is mainly located in microglial cells in a post-ischemic infarction area of China. Upregulated ULK1 is treated by LYN, so that the infarct volume is remarkably reduced, the motor function is improved, and the increase of inflammatory microglial cells is promoted. In conclusion, the ULK1 promotes the repair of neurons and promotes the formation of 13 paths of anti-inflammatory microglial cell paths after ischemic injury.
Absstract of: CN121975934A
The invention provides application of a reagent for detecting SNP sites in preparation of a product for detecting immunological rejection of organ transplantation patients. According to the present invention, the acute rejection reaction and the infection of the allogeneic organ transplantation patient can be simultaneously monitored, the genome concentration of the dd-cfDNA in the plasma can be quantified, the accurate detection of the dd-cfDNA of less than 0.5% can be achieved, the concentration calculation of the sample level can be performed on the dd-cfDNA, the sensitivity is high, and the stability is good. According to the system and the method, the physical condition of a patient subjected to allogeneic organ transplantation such as kidney transplantation, heart transplantation and lung transplantation after transplantation is regularly monitored, and a basis and a corresponding treatment scheme can be provided for dynamic monitoring and timely adjustment of the treatment scheme.
Absstract of: CN121975935A
The invention provides a primer composition for detecting hereditary thrombophilia related gene mutation and application of the primer composition, and relates to the technical field of gene detection. The primer composition comprises a PCR (Polymerase Chain Reaction) amplification primer and an extension primer, wherein the PCR amplification primer is used for carrying out specific amplification on 24 single nucleotide polymorphic sites of 22 genes, and the extension primer is used for carrying out single base extension on the 24 single nucleotide polymorphic sites. According to the primer composition, by selecting twenty-four specific loci of twenty-two genes covering key systems such as coagulation, anticoagulation and the like, a detection system which is adaptive to genetic characteristics of specific people and takes pathopoiesis and risk factors into account is constructed, so that the limitation of race heterogeneity of conventional indexes is effectively overcome; and major mutation and a multi-gene minor accumulation effect can be captured at the same time, so that individual genetic susceptibility is comprehensively analyzed, and a systematic and accurate basis is provided for accurate screening and diagnosis and treatment of hereditary thrombophilia.
Absstract of: CN121975930A
The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.
Absstract of: CN121978344A
The invention relates to application of a myocardial injury marker RSPO1 in preparation of a product for identifying cardiovascular diseases. The invention evaluates the expression profiles of all LGR4 ligands under cardiovascular diseases at present, provides the application of RSPO1 as a potential drug target, and further provides the application of the myocardial injury marker RSPO1 in preparation of products for identifying cardiovascular diseases based on the application. The invention also provides application of the reagent for detecting the RSPO1 protein level in preparation of products for diagnosing cardiovascular diseases. According to the invention, the problem of insufficient adaptability and specificity of the existing marker is solved, RSPO1 is developed into a diagnostic marker, a DY4645-05 ELISA kit is adopted for detection and adaptation of multiple samples such as serum, multiple cardiovascular diseases can be diagnosed, cross-species application is realized, a basic research and clinical diagnosis detection system is unified, and powerful support is provided for diagnosis and treatment of cardiovascular diseases.
Absstract of: CN121975928A
The invention relates to a kit for screening dilated cardiomyopathy. The kit comprises a reagent for detecting one or more of genes of TP53, TNF, IL1beta, JUN, CD8A, TLR4, UBB, CTLA4, CXCL8 and NFKBIA. The kit provided by the invention is high in detection efficiency and low in detection cost, provides important reference basis for diagnosis and prognosis judgment of patients with dilated cardiomyopathy, and can remarkably improve the survival rate of the patients.
Absstract of: CN121951024A
The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.
Absstract of: CN121951022A
The invention belongs to the field of biological detection, and discloses a gene detection panel for detecting hemangioma and vascular malformation and application of the gene detection panel. The invention discloses a gene detection panel for hemangioma and vascular malformation. Comprising the gene detection panel and is used for detecting hemangioma and vascular malformation; an application of the gene detection panel in preparation of a hemangioma and vascular malformation diagnostic reagent or diagnostic kit; the gene detection panel is applied to a device for auxiliary diagnosis of etiology of hemangioma and vascular malformation patients; and the device is used for auxiliary diagnosis of pathogenesis of hemangioma and vascular malformation patients. The gene detection panel disclosed by the invention can efficiently and accurately identify gene mutation related to hemangioma and vascular deformity, can cover wide genes related to hereditary and sporadic vascular deformity, and can provide accurate information for diagnosis, treatment and prognosis evaluation of diseases.
Absstract of: CN121951028A
The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting hypertrophic cardiomyopathy and a detection method and application thereof. The invention provides a marker for hypertrophic cardiomyopathy, the marker is CHAtRF, and the nucleotide sequence of the marker is as shown in SEQ ID NO: 1. The CHAtRF antisense nucleotide CHAtRF antiagomir can be used as an active ingredient in a product for treating hypertrophic cardiomyopathy. By using the CHAtRF antiagomir, the expression of CHAtRF in the heart can be inhibited, pathological myocardial hypertrophy can be remarkably inhibited, the fibrosis area can be reduced, and the effect of improving the heart function can be achieved, so that the purpose of preparing the medicine for preventing and/or treating hypertrophic cardiomyopathy by using the CHAtRF antiagomir as a novel gene therapy technology is achieved; and a new drug action target is provided for treatment of heart diseases related to hypertrophic cardiomyopathy.
Absstract of: WO2026086863A1
Disclosed are a method for assessing genomic DNA methylation status in a subject, a method for assessing risk for coronary heart disease (CHD) and a kit for detecting CHD or assessing CHD risk in a subject diagnosed or known risk for type 2 diabetes.
Absstract of: EP4733765A2
The present invention provides (1) a composition for improving pulmonary hypertension, comprising at least one substance capable of normalizing gut microbiota in a patient with pulmonary hypertension as an active ingredient; (2) a method for predicting the prognosis of a patient with pulmonary hypertension, or a method for assisting the determination of the severity of a patient with pulmonary hypertension, the method comprising detecting one or more types of bacteria selected from bacteria belonging to the family Micrococcaceae, Streptococcaceae, Pasteurellaceae, Veillonellaceae or Lactobacillaceae in gut microbiota in the patient with pulmonary hypertension; and (3) a method for assisting the diagnosis of pulmonary hypertension, the method comprising comparing the IgA level in feces of a subject to that of a healthy subject.
Absstract of: CN121926950A
The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of SEC24D in preparation of medicines for treating atherosclerosis. The amino acid sequence of the SEC24D is as shown in SEQ ID NO.1. The medicine is a preparation which takes the SEC24D as a target spot and can inhibit the expression of the SEC24D. Clinical data and basic experiments prove that the SEC24D plays an important role in inflammation, the mRNA level of whole blood cells of the SEC24D is increased to reflect the activation of the inflammation, and we find that the mRNA level and protein level of the SEC24D are increased in the polarization process of M1 macrophages, the expression of the macrophages SEC24D is reduced, the functions of the M1 macrophages can be inhibited, and inflammatory mediators can be reduced.
Absstract of: CN121927057A
The invention relates to application of a reagent for improving MRG15 gene expression in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of biological medicine. Based on the defects that no clear molecular marker for predicting the prognosis of the atherosclerotic patient exists at present and the existing anti-atherosclerotic medicine with the main purpose of lowering lipid cannot improve the prognosis of the patient, in order to improve the treatment effect and the prognosis of the atherosclerotic patient, follow-up visit and sample dyeing are performed on the patient, so that the prognosis of the atherosclerotic patient can be A new atherosclerosis related molecule, namely MRG15, is found, correlation between improvement of MRG15 gene expression and improvement of atherosclerosis is verified, and a new prognosis target is provided for fine management of atherosclerosis patients. In order to ensure the stability of the treatment effect, a specific agonist is screened, and an excellent anti-atherosclerosis effect is achieved. Through in-vivo verification, the plaque area is reduced by 60%-70% after the small molecule medicine litamilast is applied.
Absstract of: CN121931235A
The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting myocardial ischemia injury and a detection method and application thereof. The invention provides a marker for myocardial ischemic injury, the marker is CIAtRF, and the nucleotide sequence of the CIAtRF is as shown in SEQ ID NO: 1. The expression of CIAtRF is up-regulated during myocardial injury, and CIAtRF participates in regulation and control of myocardial ischemic injury. The CIAtRF antiagomir provided by the invention can be used as an active ingredient in a product for treating myocardial ischemia reperfusion injury. By using the CIAtRF antiagomir, the expression of CIAtRF in the heart can be inhibited, the myocardial infarction area can be obviously inhibited, the fibrosis area can be reduced, and the survival rate of myocardial cells can be increased, so that myocardial ischemic injury is relieved, and the effect of improving the cardiac function is realized.
Absstract of: CN121933737A
The invention discloses an application of NT-IGFBP-4 and GDF-15 as biomarkers in preparation of a diagnostic reagent for clinical events related to vascular plaques. Or the NT-IGFBP-4 and/or GDF-15 are/is used as a drug target to develop a drug for treating vascular plaque. When the NT-IGFBP-4 level in a biological sample is higher than the average level of healthy individuals by 13.8% or above and the NT-IGFBP-4 level in serum reaches 119.2 ng/mL or above; or when the GDF-15 level is higher than the average level of healthy individuals by 45.2% or above and the serum GDF-15 level reaches 1221 pg/mL or above, the blood vessel plaque related clinical event is basically judged; the substance for inhibiting the expression of NT-IGFBP-4 and/or GDF-15 can be used as a candidate drug for treating vascular plaque.
Absstract of: CN121931236A
The invention discloses a systemic lupus erythematosus secondary anti-phospholipid syndrome marker and application thereof, belongs to the technical field of biomedical detection, and relates to a double-sample combined diagnosis, risk stratification and targeted therapy technology. On the basis of single cell RNA sequencing and Mendel randomization data, a skin cell-peripheral blood double-sample joint detection scheme is provided, and the diagnosis sensitivity and specificity are high; an ITGA4-MIF-PTPN22 risk layering model is constructed, and accurate risk division is achieved; a transcription factor-signal channel combined intervention preparation is developed, and the thrombus inhibition rate is high; and a rapid detection test strip is designed to meet the instant detection requirement. The method solves the problems of insufficient accuracy, single target spot and lack of layering in the prior art, and has remarkable clinical value.
Absstract of: CN121931120A
The invention relates to the technical field of nucleic acid drugs and gene therapy, in particular to a preparation method and application of endothelial cell specific modRNA. The system comprises a number 1 modRNA and a number 2 modRNA, the number 1 modRNA encodes a target protein, a 5 '-untranslated region of the number 1 modRNA comprises an L7Ae protein binding element k-turn, the number 2 modRNA encodes an L7Ae protein, a 3'-untranslated region of the number 2 modRNA comprises at least one miR126 recognition sequence, and the number 1 modRNA and the number 2 modRNA are used for being delivered into an endothelial cell; the system has no genome integration risk, the expression is regulated and controlled by miR126 in real time, and the system is suitable for vascular regeneration of targeted endothelial cells, precise gene therapy of ischemic heart disease and the like.
Absstract of: CN121931264A
The invention discloses application of a reagent for detecting abundance of intestinal flora markers in preparation of a cerebral apoplexy in-vitro diagnosis product. The method comprises the following steps: performing 16S v4 region amplicon sequencing on bacterial components in faeces of healthy people and cerebral arterial thrombosis people to obtain the abundance of bacteria, finding out flora of 18 specific genus and species as microbial markers through screening operation, and constructing a cerebral arterial thrombosis risk prediction model. Verification queue data proves that the cerebral arterial thrombosis risk prediction model is high in prediction sensitivity and good in specificity, cerebral arterial thrombosis patients and healthy individuals can be effectively distinguished in multiple samples, and the accuracy is 93% or above, so that the flora can be used as a cerebral arterial thrombosis detection marker, and the cerebral arterial thrombosis risk prediction model can be used for detecting cerebral arterial thrombosis. A reagent for detecting the abundance of the intestinal flora marker can be used for preparing a cerebral arterial thrombosis in-vitro diagnosis kit, so that a foundation is laid for early diagnosis, prevention and treatment as well as research of cerebral arterial thrombosis.
Nº publicación: CN121910882A 24/04/2026
Applicant:
SHANGHAI EAST HOSPITAL TONGJI UNIV AFFILIATED EAST HOSPITAL
\u4E0A\u6D77\u5E02\u4E1C\u65B9\u533B\u9662\uFF08\u540C\u6D4E\u5927\u5B66\u9644\u5C5E\u4E1C\u65B9\u533B\u9662\uFF09
Absstract of: CN121910882A
The invention provides an application of a miR-150 inhibitor in preparation of a medicine for activating an adult myocardial cell reentry cell cycle. The invention further provides a myocardial patch, the myocardial patch contains the miR-150 inhibitor, and the miR-150 inhibitor is wrapped in intracellular delivery carriers such as lipidosome, exosome, a polymer complex and inorganic nanoparticles and is further loaded on a biodegradable hydrophilic flexible polymer film or a hydrogel material. The myocardial patch provided by the invention has good biocompatibility and biodegradability, and can be degraded and absorbed; no extra adhesive is needed, the film patch can be tightly attached to the surface of the heart by means of liquid bridge force by absorbing body fluid on the surface of the heart, and the hydrogel patch can be tightly attached to the surface of the heart by means of in-situ crosslinking on the surface of the heart to form gel. The miR-150 inhibitor can be delivered into myocardial cells to activate the proliferation potential of the myocardial cells so as to promote the proliferation of the myocardial cells of damaged myocardial tissues.
BOPI
Electronic site
